ACTA1 and metabolic dysfunction-associated steatohepatitis: In a murine model of NASH, selonsertib significantly ameliorated not only metabolic parameters associated with NASH but also decreased hepatic steatosis, inflammation and fibrosis and in a DMN-induced fibrosis rat model it could reduce collagen deposition and the expression of α-SMA, fibronectin, and collagen type I (Budas G et al. reduction of liver steatosis and fibrosis with an ASK1 inhibitor in a murine model of NASH is accomplished by improvements in cholesterol, bile acid and lipid metabolism -unpublished raw data), [217].